A Randomized Comparison of Delivered Energy in Cardioversion of Atrial Fibrillation: Biphasic Truncated Exponential Versus Pulsed Biphasic Waveforms.
Diagnostics (Basel)
; 11(6)2021 Jun 17.
Article
en En
| MEDLINE
| ID: mdl-34204498
ABSTRACT
A few randomized trials have compared impedance-compensated biphasic defibrillators in clinical use. We aim to compare pulsed biphasic (PB) and biphasic truncated exponential (BTE) waveforms in a non-inferiority cardioversion (CVS) study. This was a prospective monocentric randomized clinical trial. Eligible patients admitted for elective CVS of atrial fibrillation (AF) between February 2019 and March 2020 were alternately randomized to treatment with either a PB defibrillator (DEFIGARD TOUCH7, Schiller Médical, Wissembourg, France) or a BTE high-energy (BTE-HE) defibrillator (LIFEPAK15, Physio-Control Inc., Redmond, WA, USA). Fixed-energy protocol (200-200-200 J) was administered. CVS success was accepted if sinus rhythm was restored at 1 min post-shock. The study design considered non-inferiority testing of the primary outcome:
cumulative delivered energy (CDE). Seventy-three out of 78 randomized patients received allocated intervention 38 BTE-HE (52%), 35 PB (48%). Baseline characteristics were well-balanced between groups (p > 0.05). Both waveforms had similar CDE (mean ± standard deviation, 95% confidence interval) BTE-HE (253.9 ± 120.2 J, 214-293 J) vs. PB (226.0 ± 109.8 J, 188-264 J), p = 0.31. Indeed, effective PB shocks delivered significantly lower energies by mean of 25.6 J (95% CI 24-27.1 J, p < 0.001). Success rates were similar (BTE-HE vs. PB) 1 min first-shock (84.2% vs. 82.9%), 1 min CVS (97.4% vs. 94.3%), 2 h CVS (94.7% vs. 94.3%), 24 h CVS (92.1% vs. 94.3%), p > 0.05. Safety analysis did not find CVS hazards, reporting insignificant changes of myocardial-specific biomarkers, transient and rare ST-segment deviations, and no case of harmful tachyarrhythmias and apnea. Cardioversion of AF with fixed-energy protocol 200-200-200 J was highly efficient and safe for both PB and BTE-HE waveforms. These similar performances were achieved despite differences in the waveforms' technical design, associated with significantly lower delivered energy for the effective PB shocks. Clinical Trial Registration Registration number NCT04032678, trial register ClinicalTrials.gov.
Texto completo:
1
Bases de datos:
MEDLINE
Tipo de estudio:
Clinical_trials
/
Guideline
Idioma:
En
Revista:
Diagnostics (Basel)
Año:
2021
Tipo del documento:
Article
País de afiliación:
Bulgaria